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A 20-year-old female patient was admitted to our department due to ptosis, double vision, and
difficulty walking. The symptoms had evolved during the course of 2 months. She had never
been very athletic and was described as always having been a “slow runner,” but otherwise her
previous history was unremarkable. There was no family history of neurologic disease. There
were no preceding triggering factors such as infections, fever, or physical stress, and the patient
did not take valproate. On examination, she had bilateral external ophthalmoplegia and ptosis,
grade 4 proximal and distal paresis in the lower extremities, grade 4 distal paresis in the upper
extremities, distal sensory loss (for all sensory modalities), and sensory ataxia. After several
months, she started experiencing a very slow improvement, which is—at the present
moment—still incomplete.
MRI showed enhancement of the oculomotor nerves, the conus medullaris, the adjacent
leptomeninges, and the cauda equina nerves. In the course of 1½ years, 5 MRI scans of the
brain and medulla were performed, and the findings were stationary and independent of the
acute decline. The radiologic findings were present before a lumbar puncture was
performed.
Electroneuronography showed signs of an axonal neuropathy mainly affecting the lower
extremities. CSF examination revealed a mild pleocytosis (7 cells) [reference <5 cells/
mm3], elevated protein (22 mg/dL) [reference 20–50 mg/dL), and elevated lactate (3.3
mmol/L) [reference 1.2–2.1 mmol/L). Several repeat CSF examinations were performed
and showed the same abnormalities. CSF was negative for viruses and bacteria including
Borrelia burgdorferi, syphilis, and tuberculosis. CSF cytology and flow cytometry were
performed on 3 consecutive samples and revealed no tumor cells. Blood samples showed
normal thyroid and liver functions tests and were negative for HIV serology, hepatitis B
and C serology, tuberculosis (QuantiFERON test), syphilis, monoclonal protein, anti-
nuclear antibody, antineutrophil cytoplasmic antibodies, antiphospholipid antibodies,
angiotensin-converting enzyme, paraneoplastic antibodies, aquaporin-4 antibodies,
contactin-1 and neurofascin-155 antibodies, ganglioside antibodies (incl.GQ1B), and
acetylcholine receptor antibodies. Serum lactate was not measured. PET CT showed no
abnormalities.
The clinical phenotype was compatible with sensory ataxic neuropathy, dysarthria, and oph-
thalmoparesis. Genetic testing revealed that she was compound heterozygous for 2 pathogenic
polymerase gamma 1 (POLG) variants (c.2243G>C and c.2391G>T) located on chromosome
15. Parental DNA testing showed that the POLG variants were in trans position and therefore
responsible for the clinical phenotype. The POLG gene is essential for the function of the only
DNA polymerase that is active in mitochondria and can replicate in mitochondrial DNA
(figures 1 and 2).
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There has been only 1 previous report of abnormal nerve
enhancement in mitochondrial disease. That report in-
volved an infant patient with POLG variants whose MRI
showed oculomotor nerve and cervical root enhancement.1
The pattern of enhancement in our patient (involving the
cranial nerves, conus medullaris, and cauda equine nerve
roots) is rare and usually not associated with mitochondrial
disease. We believe that the patient has been thoroughly
investigated and has been followed clinically for more than
1 year without emergence of symptoms compatible with
a systemic condition such as an autoimmune or neoplastic
disorder. Therefore, it is considered likely that the MRI
findings are caused by the mitochondrial disorder, although
a peripheral nerve or nerve root biopsy was not performed.
POLG-related disorder can be associated with MRI changes
of the brain parenchyma. A review of 136 patients with
POLG-related epilepsy showed that stroke-like lesions were
the most prevalent abnormalities (43%), followed by thalamic
(37%), cerebellar (17%), basal ganglia (14%), and cerebral
white matter (7%) lesions. Generalized atrophy was also
prevalent (28%). No such lesions were found in our patient.2
The differential diagnoses for nerve root and conus
medullaris enhancement are very broad and include in-
fectious, autoimmune, and neoplastic disorders.3 Mito-
chondrial disease is a very rare cause of nerve enhancement.
The reason for the enhancement is not known, and it is
unclear whether it is a distinguishing property of POLG
variants or whether the enhancement is to be found in other
mitochondrial variants as well. Routine use of contrast in
the radiologic evaluation of patients with neurologic
manifestations of mitochondrial disease could help eluci-
date this.
Figure 1 Contrast-enhanced T1-weighted axial and coronal fat-saturated images showing bilateral smooth enhancement
of the oculomotor nerves (arrows)
Figure 2 Contrast-enhanced sagittal T1-weighted and axial fat-saturated images showing enhancement of the conus
medullaris (A) and cauda equina nerve roots (B) (arrows)
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With this case, we wish to highlight that POLG-associated
mitochondrial disorder should be included as a differential
diagnosis in patients with enhancement of the cranial nerves,
nerve roots, and the conus medullaris.
Study funding
J. Christensen and M. Bayat were supported by the Danish
Epilepsy Association, Central Denmark Region, and Novo
Nordisk Foundation (grant NNF16OC0019126).
Disclosure
J. Christensen reported receiving honoraria from serving
on the scientific advisory boards of and giving lectures
for UCB Nordic and Eisai AB and receiving travel
funding from UCB Nordic. The other authors have no
conflicts of interest. Go to Neurology.org/NG for full
disclosures.
Publication history
Received by Neurology: Genetics April 12, 2019. Accepted in final form
July 10, 2019.
References
1. Horst DM, Ruess L, Rusin JA, Bartholomew DW. Cranial nerve and cervical root
enhancement in an infant with polymerase gamma mutation mitochondrial disease.
Pediatr Neurol 2014;51:734–736.
2. Anagnostou ME, Ng YS, Taylor RW, McFarland R. Epilepsy due to mutations in the
mitochondrial polymerase gamma (POLG) gene:a clinical and molecular genetic
review. Epilepsia 2016;57:1531–1545.
3. Georgy BA, Snow RD, Hesselink JR. MR imaging of spinal nerve roots: techniques,
enhancement patterns, and imaging findings. AJR Am J Roentgenol 1996;166:173–179.
Appendix Authors
Name Location Role Contribution
Michael
Bayat, MD
Aarhus
University
Hospital
Author Designed and
conceptualized the study
and drafted the manuscript
Yousef
Yavarian,
MD
Aalborg
University
Hospital
Author Data collection and analysis
(radiology)
Allan Bayat,
MD
Danish
Epilepsy
Centre,
Dianalund
Author Drafting and revision of the
manuscript
Jakob
Christensen,
MD
Aarhus
University
Hospital
Author Drafting and revision for
intellectual content
Neurology.org/NG Neurology: Genetics | Volume 5, Number 5 | October 2019 3
